DepYmed is a cancer and rare disease therapeutic development company that develops inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential therapeutics for HER2-positive breast cancer and Rett Syndrome.
Company (Alive / Active)
3 Bioscience Park Drive
New York, United States
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)